Tiziana Life Sciences Ltd TLSA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -25.19M | -21.81M | -18.43M | -15.64M | -12.84M |
| Total Depreciation and Amortization | 304.00K | 269.00K | 234.00K | 192.00K | 150.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.42M | 3.35M | 2.29M | 5.08M | 7.87M |
| Change in Net Operating Assets | 7.08M | 5.07M | 3.06M | -435.00K | -3.93M |
| Cash from Operations | -13.38M | -13.11M | -12.85M | -10.80M | -8.75M |
| Capital Expenditure | -75.00K | -48.00K | -21.00K | -16.00K | -11.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 178.00K | 1.62M | 3.06M | 2.98M | 2.89M |
| Cash from Investing | 103.00K | 1.57M | 3.04M | 2.96M | 2.88M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -278.00K | -237.00K | -196.00K | -158.00K | -120.00K |
| Issuance of Common Stock | 9.39M | 9.77M | 10.15M | 11.10M | 12.05M |
| Repurchase of Common Stock | -- | -- | -- | -26.00K | -52.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 48.00K | 48.00K | 48.00K | 24.00K | -- |
| Cash from Financing | 9.16M | 9.58M | 10.01M | 10.94M | 11.88M |
| Foreign Exchange rate Adjustments | 47.00K | 65.50K | 84.00K | 98.50K | 113.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.07M | -1.89M | 286.00K | 3.20M | 6.12M |